Revision as of 00:53, 1 August 2015 by Kxl328 (talk | contribs)


Adult Dosing


  • PO: 20-40 mg q8hr, or 30-60mg (extended release) q12hr
  • IV: 5 mg/hr by slow infusion (50 ml/hr), titrate to maximum of 30 mg/hr, then maintenance of 2.0 - 15.5 mg/hr
  • IV bolus dose of 2 mg, then continuous infusion achieves same control of HTN as starting infusion without bolus[1]

Chronic Stable Angina

  • 20-40 mg PO q8hr
  • Allow 3 days between dose increase

Pediatric Dosing


  • 0.5-3 mcg/kg/min IV
  • Not approved by FDA; limited date available

Special Populations

  • Pregnancy Rating: Category C
  • Lactation: Unknown wether drug is excreted in breast milk; avoid use
  • Renal Dosing
    • Adult
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric


  • Allergy to class/drug

Adverse Reactions




  • Half-life: 2-4 hr
  • Metabolism: Metabolized in liver b CYP3A4 (first pass)
  • Excretion: urine (60%), feces (35%)
  • Mechanism of Action:
    • inhibits trasmembrane influx of extracellular calcium ions across membranes of myocardial cells and vascular smooth muscle cells without changing serum calcium concentrations; this inhibit cardiac and vascular smooth muscle contractions, thereby dilating maincoronary and systemic arteries.

See Also


  • Medscape
  1. Tao P, Zheng DY, Yu XJ. Effects of intravenous nicardipine in Chinese patients with hypertensive emergencies. Curr Ther Res Clin Exp 1998 Mar; 59: 188-95.